Goldman Sachs declares USD 304.67/share dividend on Series A preferred stock

Bitget2026/10/09 20:26

Goldman Sachs declared preferred stock dividends across multiple non-cumulative series. Largest per-share payouts: Series F USD 1,212.24; Series E USD 1,211.61. Other declared dividends include Series X USD 937.50; Series Y USD 765.63; Series O USD 662.50. Series A, C, D, O, V, X, Y dividends payable Nov. 10, 2026; record date Oct. 26, 2026. Series E, F dividends payable Dec. 1, 2026; record date Nov. 16, 2026; Series O, V to be redeemed Nov. 10, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Goldman Sachs Group Inc. published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11

4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish

BeInCrypto•2026/10/12 22:42